There have been a number of major advances in pharmacological and mechanical treatments for acute myocardial infarction. This is evident in the fact that large-scale randomized trials of aspirin and β-blockade. Despite this progress, myocardial infarction remains a major global cause of mortality and morbidity, driving a quest for novel treatments in this area. In fact, the last three decades have seen advances in ischemic conditioning, pharmacological and metabolic cardio-protection as well as biological and stem-cell therapies. This session discusses what future cardiology medicines are required including the regenerative therapies, the clinical trials, the advanced research techniques, newer drugs, the development of vaccines, extensive studies in DNA and Genetic Engineering, the role of pharmaceutical companies etc are considered for discussions and debates